SILVER SPRING, MD, USA I September 20, 2024 I Today, the U.S. Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Niemann-Pick disease, type C (NPC).

NEW YORK, NY, USA & MAINZ, Germany I, 2024 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced ...

COPENHAGEN, Denmark I 19, 2024 I Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for ...

BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 ...

LONDON, UK and CAMBRIDGE, MA, USA I September 19, 2024 I Beacon Therapeutics Holdings Limited ('Beacon' or 'the Company'), a leading ophthalmic gene therapy ...

SAN DIEGO, CA, USA & EDMONTON, Canada I 19, 2024 I Aegis Life, Inc. (Aegis) and its partner Entos® Pharmaceuticals (Entos), announced today that ...

PRINCETON, NJ, USA and SUZHOU, China I September 18, 2024 I Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated ...

EMERYVILLE, CA, USA I September 18, 2024 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company ...

Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101’s initial efficacy and safety profile and broad ...

JANESVILLE, WI, USA I 18, 2024 I GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

PHILADELPHIA, PA, USA I 18, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older ...